{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:00:18Z","timestamp":1794344418520,"version":"4.9.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2009-1039"],"award-info":[{"award-number":["2009-1039"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r\u00a0Strategisk Forskning","doi-asserted-by":"publisher","award":["IRC15-0067"],"award-info":[{"award-number":["IRC15-0067"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The hepatokine follistatin is elevated in patients with type 2 diabetes (T2D) and promotes hyperglycemia in mice. Here we explore the relationship of plasma follistatin levels with incident T2D and mechanisms involved. Adjusted hazard ratio (HR) per standard deviation (SD) increase in follistatin levels for T2D is 1.24 (CI: 1.04\u20131.47,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05) during 19-year follow-up (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094060, Sweden); and 1.31 (CI: 1.09\u20131.58,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) during 4-year follow-up (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009883, Finland). High circulating follistatin associates with adipose tissue insulin resistance and non-alcoholic fatty liver disease (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009210, Germany). In human adipocytes, follistatin dose-dependently increases free fatty acid release. In genome-wide association study (GWAS), variation in the glucokinase regulatory protein gene (\n                    <jats:italic>GCKR<\/jats:italic>\n                    ) associates with plasma follistatin levels (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094239, Sweden;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009885, UK, Italy and Sweden) and GCKR regulates follistatin secretion in hepatocytes in vitro. Our findings suggest that GCKR regulates follistatin secretion and that elevated circulating follistatin associates with an increased risk of T2D by inducing adipose tissue insulin resistance.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-26536-w","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T06:05:20Z","timestamp":1636524320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Elevated circulating follistatin associates with an increased risk of type 2 diabetes"],"prefix":"10.1038","volume":"12","author":[{"given":"Chuanyan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Born\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maykel","family":"L\u00f3pez Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Roell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-600X","authenticated-orcid":false,"given":"Jonathan M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Regmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Mansour","family":"Aly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4458-5886","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Machann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Staiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-9023","authenticated-orcid":false,"given":"Andreas L.","family":"Birkenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongya","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6120-0191","authenticated-orcid":false,"given":"Robert","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-4549","authenticated-orcid":false,"given":"Micka\u00ebl","family":"Canouil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-8293","authenticated-orcid":false,"given":"Mun-Gwan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-8449","authenticated-orcid":false,"given":"Jochen M.","family":"Schwenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-2384","authenticated-orcid":false,"given":"Emma","family":"Ahlqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-0979","authenticated-orcid":false,"given":"Minna U.","family":"Kaikkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5652-8459","authenticated-orcid":false,"given":"Peter","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3039-308X","authenticated-orcid":false,"given":"Angela C.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisel","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Natali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Melander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marju","family":"Orho-Melander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-7479","authenticated-orcid":false,"given":"Jan","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"H\u00e4ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Renstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes B.","family":"Wollheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Engstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan R.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-7604","authenticated-orcid":false,"given":"Paul W.","family":"Franks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris F.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Duffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan Arthur","family":"Vaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3394-7749","authenticated-orcid":false,"given":"Markku","family":"Laakso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2186-9595","authenticated-orcid":false,"given":"Norbert","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0187-3263","authenticated-orcid":false,"given":"Leif","family":"Groop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8081-2142","authenticated-orcid":false,"given":"Yang","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"26536_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/dmrr.2415","volume":"29","author":"J Hansen","year":"2013","unstructured":"Hansen, J. et al. Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation. Diabetes Metab. Res Rev. 29, 463\u2013472 (2013).","journal-title":"Diabetes Metab. Res Rev."},{"key":"26536_CR2","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1038\/ajg.2009.318","volume":"104","author":"A Yndestad","year":"2009","unstructured":"Yndestad, A. et al. A complex role of activin A in non-alcoholic fatty liver disease. Am. J. Gastroenterol. 104, 2196\u20132205 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"26536_CR3","doi-asserted-by":"publisher","first-page":"16239","DOI":"10.1073\/pnas.0705971104","volume":"104","author":"KL Jones","year":"2007","unstructured":"Jones, K. L. et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl Acad. Sci. USA 104, 16239\u201316244 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26536_CR4","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1371\/journal.pone.0000789","volume":"2","author":"SJ Lee","year":"2007","unstructured":"Lee, S. J. Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One 2, e789 (2007).","journal-title":"PLoS One"},{"key":"26536_CR5","doi-asserted-by":"publisher","first-page":"R235","DOI":"10.1152\/ajpregu.91020.2008","volume":"297","author":"EF Medeiros","year":"2009","unstructured":"Medeiros, E. F., Phelps, M. P., Fuentes, F. D. & Bradley, T. M. Overexpression of follistatin in trout stimulates increased muscling. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297, R235\u2013R242 (2009).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"26536_CR6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1126\/science.2106159","volume":"247","author":"T Nakamura","year":"1990","unstructured":"Nakamura, T. et al. Activin-binding protein from rat ovary is follistatin. Science 247, 836\u2013838 (1990).","journal-title":"Science"},{"key":"26536_CR7","doi-asserted-by":"publisher","first-page":"9306","DOI":"10.1073\/pnas.151270098","volume":"98","author":"SJ Lee","year":"2001","unstructured":"Lee, S. J. & McPherron, A. C. Regulation of myostatin activity and muscle growth. Proc. Natl Acad. Sci. USA 98, 9306\u20139311 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26536_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/ng0997-71","volume":"17","author":"L Grobet","year":"1997","unstructured":"Grobet, L. et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat. Genet 17, 71\u201374 (1997).","journal-title":"Nat. Genet"},{"key":"26536_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron, A. C., Lawler, A. M. & Lee, S. J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83\u201390 (1997).","journal-title":"Nature"},{"key":"26536_CR10","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1126\/science.1069525","volume":"296","author":"TA Zimmers","year":"2002","unstructured":"Zimmers, T. A. et al. Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486\u20131488 (2002).","journal-title":"Science"},{"key":"26536_CR11","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa040933","volume":"350","author":"M Schuelke","year":"2004","unstructured":"Schuelke, M. et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med 350, 2682\u20132688 (2004).","journal-title":"N. Engl. J. Med"},{"key":"26536_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1194\/jlr.M039719","volume":"55","author":"M Braga","year":"2014","unstructured":"Braga, M. et al. Follistatin promotes adipocyte differentiation, browning, and energy metabolism. J. Lipid Res 55, 375\u2013384 (2014).","journal-title":"J. Lipid Res"},{"key":"26536_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1210\/jc.2015-3668","volume":"101","author":"JS Hansen","year":"2016","unstructured":"Hansen, J. S. et al. Circulating Follistatin Is Liver-Derived and Regulated by the Glucagon-to-Insulin Ratio. J. Clin. Endocrinol. Metab. 101, 550\u2013560 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"26536_CR14","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/mt.2015.29","volume":"23","author":"C Zhao","year":"2015","unstructured":"Zhao, C. et al. Overcoming Insulin Insufficiency by Forced Follistatin Expression in beta-cells of db\/db Mice. Mol. Ther. 23, 866\u2013874 (2015).","journal-title":"Mol. Ther."},{"key":"26536_CR15","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41591-018-0048-0","volume":"24","author":"R Tao","year":"2018","unstructured":"Tao, R. et al. Inactivating hepatic follistatin alleviates hyperglycemia. Nat. Med 24, 1058\u20131069 (2018).","journal-title":"Nat. Med"},{"key":"26536_CR16","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.2337\/db08-0516","volume":"57","author":"M Orho-Melander","year":"2008","unstructured":"Orho-Melander, M. et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57, 3112\u20133121 (2008).","journal-title":"Diabetes"},{"key":"26536_CR17","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1210\/jc.2017-00948","volume":"102","author":"Y Borne","year":"2017","unstructured":"Borne, Y. et al. Complement C3 Associates With Incidence of Diabetes, but No Evidence of a Causal Relationship. J. Clin. Endocrinol. Metab. 102, 4477\u20134485 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"26536_CR18","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1093\/hmg\/ddp357","volume":"18","author":"NL Beer","year":"2009","unstructured":"Beer, N. L. et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum. Mol. Genet 18, 4081\u20134088 (2009).","journal-title":"Hum. Mol. Genet"},{"key":"26536_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s00125-011-2348-5","volume":"55","author":"MG Rees","year":"2012","unstructured":"Rees, M. G. et al. Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 55, 114\u2013122 (2012).","journal-title":"Diabetologia"},{"key":"26536_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0453-x","volume":"9","author":"M Lopez","year":"2017","unstructured":"Lopez, M. Rodriguez et al., Identification and characterization of a FOXA2-regulated transcriptional enhancer at a type 2 diabetes intronic locus that controls GCKR expression in liver cells. Genome Med 9, 63 (2017).","journal-title":"Genome Med"},{"key":"26536_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature12724","volume":"504","author":"DJ Lloyd","year":"2013","unstructured":"Lloyd, D. J. et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors.Nature 504, 437\u2013440 (2013).","journal-title":"Nature"},{"key":"26536_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00018-008-8322-9","volume":"66","author":"Iynedjian P","year":"2009","unstructured":"Iynedjian, P. B. Molecular physiology of mammalian glucokinase. Cell Mol Life Sci. 66, 27\u201342 (2009).","journal-title":"Cell Mol Life Sci"},{"key":"26536_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cmet.2017.07.008","volume":"26","author":"N Stefan","year":"2017","unstructured":"Stefan, N., Schick, F. & Haring, H. U. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metab. 26, 292\u2013300 (2017).","journal-title":"Cell Metab"},{"key":"26536_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrendo.2014.185","volume":"11","author":"F Karpe","year":"2015","unstructured":"Karpe, F. & Pinnick, K. E. Biology of upper-body and lower-body adipose tissue\u2013link to whole-body phenotypes. Nat Rev Endocrinol. 11, 90\u2013100 (2015).","journal-title":"Nat Rev Endocrinol"},{"key":"26536_CR25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2337\/diabetes.52.2.260","volume":"52","author":"P Staehf","year":"2003","unstructured":"Staehr, P. et al. Effects of free fatty acids per se on glucose production, gluconeogenesis, and glycogenolysis. Diabetes. 52, 260\u2013267 (2003).","journal-title":"Diabetes"},{"key":"26536_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1530\/eje.0.1350345","volume":"135","author":"Y Sakamoto","year":"1996","unstructured":"Sakamoto, Y. et al. Determination of free follistatin levels in sera of normal subjects and patients with various diseases. Eur J Endocrinol. 135, 345\u2013351 (1996).","journal-title":"Eur J Endocrinol"},{"key":"26536_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1210\/en.2010-0868","volume":"152","author":"J Hansen","year":"2011","unstructured":"Hansen, J. et al. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine. Endocrinology. 152, 164\u2013171 (2011).","journal-title":"Endocrinology"},{"key":"26536_CR28","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1210\/jc.2011-1665","volume":"96","author":"MT Vamvini","year":"2011","unstructured":"Vamvini, M. T., Aronis, K. N., Chamberland, J. P. & Mantzoros, C. S. Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males. J Clin Endocrinol Metab. 96, 3416\u20133426 (2011).","journal-title":"J Clin Endocrinol Metab"},{"key":"26536_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/MOL.0000000000000155","volume":"26","author":"A Raimondo","year":"2015","unstructured":"Raimondo, A., Rees, M. G. & Gloyn, A. L. Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism. Curr Opin Lipidol. 26, 88\u201395 (2015).","journal-title":"Curr Opin Lipidol"},{"key":"26536_CR30","doi-asserted-by":"publisher","first-page":"7826","DOI":"10.1074\/jbc.275.11.7826","volume":"275","author":"J Grimsby","year":"2000","unstructured":"Grimsby, J. et al. Characterization of glucokinase regulatory protein-deficient mice. J Biol Chem. 275, 7826\u20137831 (2000).","journal-title":"J Biol Chem"},{"key":"26536_CR31","doi-asserted-by":"publisher","first-page":"7377","DOI":"10.3390\/ijms16047377","volume":"16","author":"L Jin","year":"2015","unstructured":"Jin, L. et al. Role of glucokinase in the subcellular localization of glucokinase regulatory protein. Int J Mol Sci. 16, 7377\u20137393 (2015).","journal-title":"Int J Mol Sci"},{"key":"26536_CR32","doi-asserted-by":"publisher","first-page":"14511","DOI":"10.1073\/pnas.96.25.14511","volume":"96","author":"D Farrelly","year":"1999","unstructured":"Farrelly, D. et al. Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation. Proc Natl Acad Sci USA. 96, 14511\u201314516 (1999).","journal-title":"Proc Natl Acad Sci USA"},{"key":"26536_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.molmed.2015.08.004","volume":"21","author":"M Brouwers","year":"2015","unstructured":"Brouwers, M., Jacobs, C., Bast, A., Stehouwer, C. D. A. & Schaper, N. C. Modulation of glucokinase regulatory protein: A double-edged sword? Trends Mol Med. 21, 583\u2013594 (2015).","journal-title":"Trends Mol Med"},{"key":"26536_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ebiom.2017.11.023","volume":"26","author":"I Mattisson","year":"2017","unstructured":"Mattisson, I. Y. et al. Elevated markers of death receptor-activated apoptosis are associated with increased risk for development of diabetes and cardiovascular disease. EBioMedicine. 26, 187\u2013197 (2017).","journal-title":"EBioMedicine"},{"key":"26536_CR35","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 9, e95192 (2014).","journal-title":"PLoS One"},{"key":"26536_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00125-018-4751-7","volume":"62","author":"X Bao","year":"2019","unstructured":"Bao, X. et al. Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmo Diet and Cancer-Cardiovascular Cohort. Diabetologia. 62, 78\u201386 (2019).","journal-title":"Diabetologia"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26536-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26536-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26536-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T12:19:52Z","timestamp":1669983592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26536-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["26536"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-26536-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.C.R., J.M.W., A.R., and K.L.D. are employees at Eli Lilly. A patent application has been filed on follistatin and diabetes risk by YDM. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6486"}}